Literature DB >> 26998529

Perils of Pragmatic Psychiatry: How We Can Do Better.

Maju Mathew Koola1, Joseph Sebastian2.   

Abstract

Etiologic and pathophysiologic understanding of psychiatric disorders is still in its early stages. The neurobiology of major psychiatric disorders has yet to be fully elucidated. Psychiatric diagnoses are often based on presenting symptoms, lacking reliability and stability. For a variety of reasons, many notable laboratory and clinical observations have not been tested in large trials. Lacking this validation, these potentially valuable practices have not been widely disseminated nor translated into real world practice. Pragmatic practice today requires optimum use of the available resources. This may sometimes require translating novel treatments supported by strong, evidence-based, level II evidence; but still lacking level I evidence into practice and greater utilization of evidence-based approved practices. The purpose of this paper is to highlight some common avoidable pitfalls in practice, and to offer a few psychopharmacological pearls.

Entities:  

Keywords:  Alcohol; Anxiety; Bipolar; Depression; Insomnia; PTSD; Pragmatic psychiatry; Psychiatry practice; Psychopharmacology; Schizophrenia; Substance; Suicide; Treatment

Year:  2016        PMID: 26998529      PMCID: PMC4795475          DOI: 10.24966/pda-0150/100002

Source DB:  PubMed          Journal:  HSOA J Psychiatry Depress Anxiety


  112 in total

1.  Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium.

Authors:  L Tune; S Carr; E Hoag; T Cooper
Journal:  Am J Psychiatry       Date:  1992-10       Impact factor: 18.112

2.  Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.

Authors:  Kosuke Matsuzono; Nozomi Hishikawa; Yasuyuki Ohta; Toru Yamashita; Kentaro Deguchi; Yumiko Nakano; Koji Abe
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Drug levels and antiparkinsonian drugs in neuroleptic-treated schizophrenic patients.

Authors:  A Hitri; R B Craft; R Sethi; D Sinha
Journal:  Clin Neuropharmacol       Date:  1987-06       Impact factor: 1.592

4.  The European Psychiatric Association (EPA) guidance on suicide treatment and prevention.

Authors:  D Wasserman; Z Rihmer; D Rujescu; M Sarchiapone; M Sokolowski; D Titelman; G Zalsman; Z Zemishlany; V Carli
Journal:  Eur Psychiatry       Date:  2011-12-01       Impact factor: 5.361

5.  Declining benzodiazepine use in veterans with posttraumatic stress disorder.

Authors:  Brian C Lund; Nancy C Bernardy; Bruce Alexander; Matthew J Friedman
Journal:  J Clin Psychiatry       Date:  2011-11-29       Impact factor: 4.384

Review 6.  [Schizoaffective Disorder: Evolution and Current Status of the Concept].

Authors:  Susanta Padhy; Aditya Hedge
Journal:  Turk Psikiyatri Derg       Date:  2015

Review 7.  One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review.

Authors:  Christoph U Correll; John M Kane
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-10       Impact factor: 2.576

8.  Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

Authors:  Carlos A Zarate; Jennifer L Payne; Jaskaran Singh; Jorge A Quiroz; David A Luckenbaugh; Kirk D Denicoff; Dennis S Charney; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2004-07-01       Impact factor: 13.382

9.  Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis.

Authors:  Alireza Atri; Suzanne B Hendrix; Vojislav Pejović; Robert K Hofbauer; John Edwards; José Luis Molinuevo; Stephen M Graham
Journal:  Alzheimers Res Ther       Date:  2015-05-18       Impact factor: 6.982

Review 10.  EMSAM (deprenyl patch): how a promising antidepressant was underutilized.

Authors:  Gregory M Asnis; Margaret A Henderson
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.